Date
|
Update
|
15 May 2025
|
The Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232].
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
|
21 January 2025 - 18 February 2025
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6232 |
21 January 2025
|
In progress. Scoping commencing |
16 December 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |